Hy Levitsky
Impact in
- Immunology top 1%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Oncology top 2%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Immunotherapy and Immune Responses 7
- T-cell and B-cell Immunology 1
- Oncology 9
- CAR-T cell therapy research 7
- Cancer Immunotherapy and Biomarkers 3
- Co-authors
- Drew M. PardollElizabeth M. JaffeeGlen DranoffA LazenbyPaul T. GolumbekRichard C. MulliganHirotaka HamadaKatja Brose
- Journals
- Blood (3 papers)Molecular Therapy (1 paper)The Journal of Urology (1 paper)Immunologic Research (1 paper)Gene Therapy (1 paper)
- Partner nations
- United States
In The Last Decade
Hy Levitsky
10 papers receiving 2.8k citations
Hit Papers
Peers
Comparison fields: 5 of 79
- Immunology 2.2k
- Oncology 1.5k
- Biotechnology 288
- Genetics 757
- Molecular Biology 949
Countries citing papers authored by Hy Levitsky
This map shows the geographic impact of Hy Levitsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hy Levitsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hy Levitsky more than expected).
Fields of papers citing papers by Hy Levitsky
This network shows the impact of papers produced by Hy Levitsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hy Levitsky. The network helps show where Hy Levitsky may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Hy Levitsky, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2024 | 3 | |
| 3 | 2024 | 0 | |
| 4 | 2017 | 27 | |
| 5 | 2016 | 25 | |
| 6 | 2014 | 106 | |
| 7 | 2006 | 44 | |
| 8 | 1998 | 329 | |
| 9 | Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Hit paper breakdown → | 1993 | 2310 |
| 10 | 1993 | 16 | |
| 11 | 1992 | 1 |
About Hy Levitsky
Hy Levitsky is a scholar working on Immunology, Oncology, Genetics, Infectious Diseases and Molecular Biology, having authored 11 papers that have together received 2.9k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (7 papers), CAR-T cell therapy research (7 papers), Virus-based gene therapy research (4 papers), Cancer Immunotherapy and Biomarkers (3 papers), RNA Interference and Gene Delivery (1 paper), Viral gastroenteritis research and epidemiology (1 paper), Bacteriophages and microbial interactions (1 paper) and T-cell and B-cell Immunology (1 paper). The work is most often cited by research in Immunology (2.2k citations), Oncology (1.5k citations), Biotechnology (288 citations), Genetics (757 citations) and Molecular Biology (949 citations). Hy Levitsky has collaborated with scholars based in United States. Frequent co-authors include Drew M. Pardoll, Elizabeth M. Jaffee, Glen Dranoff, A Lazenby, Paul T. Golumbek, Richard C. Mulligan, Hirotaka Hamada, Katja Brose, Young J. Kim and Deepak K. Kadayakkara. Their work appears in journals such as Blood, Molecular Therapy, The Journal of Urology, Immunologic Research and Gene Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.